Logo ofDallah Healthcare Co.
Dallah Healthcare mulls the purchase of Growth Avenue’s entire ownership of 41.36% in Care Shield Holding Co. Upon completion of this transaction, Dallah will own 100% of the share capital of Care Shield Holding Co. 
The companies clarified that the MoU represents a preliminary, non-binding agreement in relation to the potential transaction, under which both parties agreed to negotiate in good faith to reach a final binding agreement and to enable Dallah Healthcare to conduct due diligence on the target company.
The MoU also includes customary provisions, such as confidentiality clauses and other standard terms.
The MoU was signed on Oct. 26 and will remain effective until Nov. 30, 2025.
Both companies stated that there are no related parties in the transaction.
It was noted that Care Shield Holding, 41.36% owned by Growth Avenue and 58.64% owned by Dallah Healthcare, is not a direct party to the MoU.
There is no financial impact at present, and Growth Avenue will negotiate the final binding terms of the share purchase agreement should Dallah Healthcare complete its due diligence process. The parties will then proceed to obtain any necessary regulatory approvals.
Dallah Healthcare appointed Ziad Samir Khoshaim Law Firm (Khoshaim Associates) as its legal advisor for the potential transaction, while no financial advisors have been appointed by either party to date.
The MoU is non-binding, and that the completion of the potential transaction remains subject to the parties reaching a final binding agreement. There is no assurance that such final agreements will be signed or that the transaction will be completed.
Any material developments in accordance with applicable regulations will be revealed in due course.
Logo ofDallah Healthcare Co.
Dallah Healthcare mulls the purchase of Growth Avenue’s entire ownership of 41.36% in Care Shield Holding Co. Upon completion of this transaction, Dallah will own 100% of the share capital of Care Shield Holding Co.
The companies clarified that the MoU represents a preliminary, non-binding agreement in relation to the potential transaction, under which both parties agreed to negotiate in good faith to reach a final binding agreement and to enable Dallah Healthcare to conduct due diligence on the target company.
The MoU also includes customary provisions, such as confidentiality clauses and other standard terms.
The MoU was signed on Oct. 26 and will remain effective until Nov. 30, 2025.
Both companies stated that there are no related parties in the transaction.
It was noted that Care Shield Holding, 41.36% owned by Growth Avenue and 58.64% owned by Dallah Healthcare, is not a direct party to the MoU.
There is no financial impact at present, and Growth Avenue will negotiate the final binding terms of the share purchase agreement should Dallah Healthcare complete its due diligence process. The parties will then proceed to obtain any necessary regulatory approvals.
Dallah Healthcare appointed Ziad Samir Khoshaim Law Firm (Khoshaim Associates) as its legal advisor for the potential transaction, while no financial advisors have been appointed by either party to date.
The MoU is non-binding, and that the completion of the potential transaction remains subject to the parties reaching a final binding agreement. There is no assurance that such final agreements will be signed or that the transaction will be completed.
Any material developments in accordance with applicable regulations will be revealed in due course.
